Mobica 7.5 Mg/ Mobica 15 Mg 7.5 mg/ 15 mg Tablet
PDF Leaflet Revision Date: 13 December 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Symptomatic treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and acute sciatica.
Dosage (summary)
7.5 mg to 15 mg once daily, depending on condition and response.
Onset of Action / Duration
Onset: 5-6 hours, Duration: 13-25 hours
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; may impair fertility.
Key Drug Interactions
- Increased risk of bleeding with anticoagulants
- Increased lithium levels
- Reduced effect of antihypertensives
Contraindications
- Hypersensitivity to meloxicam
- Active gastrointestinal disease
- Severe hepatic or renal insufficiency
- Pregnancy and lactation
- Children under 12 years
Common side effects
- Gastrointestinal disturbances
- Headache
- Dizziness
- Rash
Counselling Points
- Take with food and water
- Monitor for gastrointestinal symptoms
- Avoid driving if experiencing dizziness or visual disturbances
Serious warnings
- Risk of gastrointestinal bleeding and perforation
- Serious skin reactions
- Cardiovascular thrombotic events
Important Disclaimer
The Mobica 7.5 Mg/ Mobica 15 Mg 7.5 mg/ 15 mg Tablet professional information leaflet below is the property of Ingelheim Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
